Host: |
Rabbit |
Applications: |
WB/IHC/IF/ELISA |
Reactivity: |
Human/Mouse |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-Phospho-MAP kinase-activated protein kinase 5-Thr182 (148-197 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
Concentration: |
1 mg/mL |
Dilution Range: |
WB 1:500-1:2000IHC 1:100-1:300ELISA 1:5000IF 1:50-200 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
MAPKAPK5 |
Gene ID: |
8550 |
Uniprot ID: |
MAPK5_HUMAN |
Immunogen Region: |
148-197 aa |
Specificity: |
Phospho-PRAK (T182) Polyclonal Antibody detects endogenous levels of PRAK protein only when phosphorylated at T182. |
Immunogen: |
The antiserum was produced against synthesized peptide derived from the human MAPKAPK5 around the phosphorylation site of Thr182 at the amino acid range 148-197 |
Post Translational Modifications | Phosphorylated on Thr-182 ERK3/MAPK6 or ERK4/MAPK4.which is the regulatory phosphorylation site and is located on the T-loop/loop 12, leading to activation. Phosphorylation at Thr-182 by p38-alpha/MAPK14, p38-beta/MAPK11 is subject to debate. Phosphorylated at Ser-115 by PKA/PRKACA, leading to localization to the cytoplasm. Autophosphorylated. |
Function | Tumor suppressor serine/threonine-protein kinase involved in mTORC1 signaling and post-transcriptional regulation. Phosphorylates FOXO3, ERK3/MAPK6, ERK4/MAPK4, HSP27/HSPB1, p53/TP53 and RHEB. Acts as a tumor suppressor by mediating Ras-induced senescence and phosphorylating p53/TP53. Involved in post-transcriptional regulation of MYC by mediating phosphorylation of FOXO3: phosphorylation of FOXO3 leads to promote nuclear localization of FOXO3, enabling expression of miR-34b and miR-34c, 2 post-transcriptional regulators of MYC that bind to the 3'UTR of MYC transcript and prevent MYC translation. Acts as a negative regulator of mTORC1 signaling by mediating phosphorylation and inhibition of RHEB. Part of the atypical MAPK signaling via its interaction with ERK3/MAPK6 or ERK4/MAPK4: the precise role of the complex formed with ERK3/MAPK6 or ERK4/MAPK4 is still unclear, but the complex follows a complex set of phosphorylation events: upon interaction with atypical MAPK (ERK3/MAPK6 or ERK4/MAPK4), ERK3/MAPK6 (or ERK4/MAPK4) is phosphorylated and then mediates phosphorylation and activation of MAPKAPK5, which in turn phosphorylates ERK3/MAPK6 (or ERK4/MAPK4). Mediates phosphorylation of HSP27/HSPB1 in response to PKA/PRKACA stimulation, inducing F-actin rearrangement. |
Protein Name | Map Kinase-Activated Protein Kinase 5Mapk-Activated Protein Kinase 5Mapkap Kinase 5Mapkap-K5Mapkapk-5Mk-5Mk5P38-Regulated/Activated Protein KinasePrak |
Database Links | Reactome: R-HSA-2559580Reactome: R-HSA-5687128Reactome: R-HSA-6804756 |
Cellular Localisation | CytoplasmNucleusTranslocates To The Cytoplasm Following Phosphorylation And ActivationInteraction With Erk3/Mapk6 Or Erk4/Mapk4 And Phosphorylation At Thr-182Activates The Protein Kinase ActivityFollowed By Translocation To The CytoplasmPhosphorylation By Pka/Prkaca At Ser-115 Also Induces Nuclear Export |
Alternative Antibody Names | Anti-Map Kinase-Activated Protein Kinase 5 antibodyAnti-Mapk-Activated Protein Kinase 5 antibodyAnti-Mapkap Kinase 5 antibodyAnti-Mapkap-K5 antibodyAnti-Mapkapk-5 antibodyAnti-Mk-5 antibodyAnti-Mk5 antibodyAnti-P38-Regulated/Activated Protein Kinase antibodyAnti-Prak antibodyAnti-MAPKAPK5 antibodyAnti-PRAK antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance